Approaches to Left Atrial Appendage Closure: Device Design, Performance, and Limitations

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


Up to 6.1 million people in the United States have atrial fibrillation (AF), which is associated with an increased risk of stroke. Oral anticoagulants are the mainstay of stroke prevention in AF. For decades, warfarin was the only available drug, fraught with compliance limitations, a narrow therapeutic window, and a high risk of hemorrhage. Pharmacologic developments have produced new anticoagulants that have improved the rates of stroke related to AF; however, they still confer a high risk of bleeding, making them unsuitable for some patients. Studies have shown that roughly 90% of strokes in patients with AF occur in the left atrial appendage (LAA). This understanding has prompted the development and testing of novel percutaneous strategies for LAA closure as an alternative to anticoagulation therapy. The following review examines the relative merits and shortcomings of these strategies and explores future prospects in the prevention of AF-related stroke.

Original languageEnglish (US)
Pages (from-to)106-113
Number of pages8
JournalMethodist DeBakey cardiovascular journal
Issue number3
StatePublished - Jul 1 2017


  • atrial fibrillation
  • cardioembolic stroke
  • left atrial appendage
  • percutaneous LAA closure
  • stroke
  • thromboembolism

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Approaches to Left Atrial Appendage Closure: Device Design, Performance, and Limitations'. Together they form a unique fingerprint.

Cite this